NCT04894890Completed
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
Source: ClinicalTrials.gov · Last updated 20 Mar 2024
Brief summary (registry, in English)
This non-interventional, prospective, multi-center study aims to provide short- and long- term treatment patterns, effectiveness, and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis (with and without PsA) initiating treatment of secukinumab.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1002 (actual)
- First submitted
- 18 May 2021
- Start date
- 26 Sept 2021
- Primary completion date
- 15 Dec 2023
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Psoriasis
- NCT number
- NCT04894890
What you commit to
- Study type: Observational
- Participants enrolled: 1002
- From 26 Sept 2021 to the primary completion date, 15 Dec 2023
- 29 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Participation in any dermatology or rheumatology clinical trial, concurrent or within the last 30 days of the secukinumab initiating date
Who the study is looking for
- Aged ≥ 18 years;
- Diagnosis of clinically moderate to severe plaque-psoriasis;
- Initiating treatment with secukinumab during the identification period or within 30 days prior to the index date;
- Patient agrees to sign the informed consent
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (29)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.